Trial Termination

Galecto terminates development for its lead candidate

Galecto has axed the development of its lead pipeline candidate, GB0139, after announcing that the Phase IIb trial for the…

Palisade Bio terminates its post-surgical abdominal adhesions treatment trial

Palisade Bio has terminated the development of its lead clinical candidate, tranexamic acid (LB1148), for reducing intra-abdominal adhesions in patients…